Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr

Journal of Lipid Research

Volumn 41, Issue 11, 2000, Pages 1760-1771

  Liu, H ^a   Labeur, C ^a   Xu, C F ^a   Ferrell, R ^a   Lins, L ^a   Brasseur, R ^a   Rosseneu, M ^a   Weiss, K M ^a   Humphries, S E ^a   Talmud, P J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

apoE displacement; DMPC; Genetic variation; Lipid binding; LPL inhibition

Indexed keywords

ALANINE; APOLIPOPROTEIN C; DIMYRISTOYLPHOSPHATIDYLCHOLINE; LIPOPROTEIN LIPASE; THREONINE; TRIACYLGLYCEROL;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME INHIBITION; ESCHERICHIA COLI; EXON; FEMALE; GENE MUTATION; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INDIAN; LIPOLYSIS; LIPOPROTEIN DEFICIENCY; MALE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; PROTEIN VARIANT; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; AMINO ACID SEQUENCE; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; APOLIPOPROTEINS E; CENTRAL AMERICA; CHEMISTRY, PHYSICAL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DNA MUTATIONAL ANALYSIS; ENZYME INHIBITORS; HUMANS; INDIANS, CENTRAL AMERICAN; LIPID METABOLISM; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS;

EID: 0033738797     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Disorders of lipoprotein and lipid metabolism
2. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII
3. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: Implications for the regulation of the catabolism of these lipoproteins
4. Apolipoproteins C-II and C-III in serum quantified by zone immunoelectrophoresis
5. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E
6. Influence of apolipoproteins on the anatomical distribution of arterial disease
7. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound
8. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
9. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
10. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo
11. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III
12. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat
13. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver
14. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway
15. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia
16. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice
17. DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease
18. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein
19. Linkage of human apolipoproteins A-I and C-III genes
20. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease
21. Association between genetic variation at the APO AI-CIII-AIV gene cluster and familial combined hyperlipidaemia
22. DNA polymorphism adjacent to human apoprotein A-1 gene: Relation to hypertriglyceridaemia
23. Genetic variation in the apolipoprotein AI-CIII-AIV gene cluster and coronary heart disease
24. Apolipoprotein C-III gene variation and dyslipidaemia
25. Deoxyribonucleic acid polymorphism in the apolipoprotein A-1-C-III gene cluster. Association with hypertriglyceridemia
26. Genetic polymorphisms of apolipoprotein C-III and insulin in survivors of myocardial infarction
27. DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis
28. Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11
29. Apolipoprotein C-III(Lys58→Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia
30. Molecular cloning of a human apoC-III variant: Thr 74→Ala 74 mutation prevents O-glycosylation
31. Electrophoretic screening for genetic variation in apolipoprotein C-III: Identification of a novel apoC-III variant, apoC-III(Asp45→Asn), in a Turkish patient
32. A novel apolipoprotein C-III variant, apoC-III(Gln38→Lys), associated with moderate hypertriglyceridemia in a large kindred of Mexican origin
33. Genetic variation in the apolipoproteins C-II and C-III
34. Immunochemical quantitation of antigens by single radial immunodiffusion
35. Enzymatic determination of total serum cholesterol
36. DNA polymorphisms of the apolipoprotein AI/CIII/AIV gene cluster influence plasma cholesterol and triglyceride levels in the Mayans of the Yucatan Peninsula, Mexico
37. Molecular modeling of the amphipathic helices of the plasma apolipoproteins
38. Theoretical analysis of molecular membrane organization
39. Differentiation of lipid-associating helices by use of three-dimensional molecular hydrophobicity potential calculations
40. SOPMA: Significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments
41. Prediction of protein secondary structure at better than 70% accuracy
42. Combining evolutionary information and neural networks to predict protein secondary structure
43. Incorporation of non-local interactions in protein secondary structure prediction from the amino acid sequence
44. GOR method for predicting protein secondary structure from amino acid sequence
45. An algorithm for protein secondary structure prediction based on class prediction
46. Identification and application of the concepts important for accurate and reliable protein secondary structure prediction
47. An algorithm for secondary structure determination in proteins based on sequence similarity
48. Exploring the limits of nearest neighbour secondary structure prediction
49. Improved performance in protein secondary structure prediction by inhomogeneous score combination
50. Comparison of lipid-binding and lecithin:cholesterol acyltransferase activation of the amino- and carboxyl-terminal domains of human apolipoprotein E3
51. Displacement of apo A-I from HDI, by apo A-II or its C-terminal helix promotes the formation of pre-betal migrating particles and decreases LCAT activation
52. Single-step purification of two functional human apolipoprotein E variants hyperexpressed in Escherichia coli
53. Apolipoprotein structure, function and measurement
54. Quantification of human serum apolipoprotein AI by enzyme immunoassay
55. Assay of lipoprotein lipase and hepatic lipase
56. Composition of very low density lipoproteins and in vitro effect of lipoprotein lipase
57. Characterization of C-terminal histidine-tagged human recombinant lecithin:cholesterol acyltransferase
58. ApoC-III gene variants modulate postprandial response to both glucose and fat tolerance tests
59. Primary structure of the bovine analogues to human apolipoproteins CII and CIII. Studies on isoforms and evidence for proteolytic processing
60. The apolipoprotein multigene family: Biosynthesis, structure, structure-function relationships, and evolution
61. Structure and evolution of the apolipoprotein multigene family
62. Structure and expression of dog apolipoprotein C-II and C-III mRNAs. Implications for the evolution and functional constraints of apolipoprotein structure
63. Lipid-binding properties of apolipoproteins
64. The lipid-free structure of apolipoprotein A-I: Effects of amino-terminal deletions
65. Characterization of human apolipoprotein A-I expressed in Escherichia coli
66. Apolipoprotein A-I (R151C) Paris is defective in activation of lecithin:cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux
67. The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: Role in receptor-binding activity
68. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles
69. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice
70. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E
71. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein
72. 5-Dimethylaminonaphthalene-1-sulfonyl 3-aminotyrosyl apolipoprotein C-III. Preparation, characterization, and interaction with phospholipid vesicles
73. Only multimers of a synthetic peptide of human apolipoprotein E are biologically active